Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIO-301 in Retinitis Pigmentosa and Choroideremia (ABACUS)
NCT05282953Phase 2Completed
- Sponsor
- Kiora Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of KIO-301 in retinitis pigmentosa (RP), choroideremia, Retinitis Pigmentosa (RP), sponsored by Kiora Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
KIO-301
03
Conditions
retinitis pigmentosa (RP)choroideremiaRetinitis Pigmentosa (RP)
Beyond the preview
Go deeper on NCT05282953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05282953.